Vireo Growth (VREOF) Payables (2020 - 2026)
Vireo Growth (VREOF) posted Payables of $58.3 million for Q1 2026, up 15.45% sequentially from $50.5 million in Q4 2025, and up 801.93% YoY from $6.5 million in Q1 2025.
Vireo Growth (VREOF) Payables (2020 - 2026) Analysis & Trends
Vireo Growth has reported Payables for 7 years, with the latest figure at $58.3 million in Q1 2026.
- Quarterly Payables rose 801.93% year-over-year to $58.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.3 million (up 801.93% YoY) and the FY2025 annual result came in at $50.5 million, up 2097.51% from the prior year.
- Payables grew to $58.3 million in Q1 2026 per VREOF's latest filing, from $50.5 million in the prior quarter.
- Over five years, Payables peaked at $58.3 million in Q1 2026 and troughed at $1.5 million in Q3 2023.
- A 5-year average of $17.6 million and a median of $14.9 million in 2022 frame the typical range for Payables.
- The sharpest annual moves came in 2023 and 2025: Payables slumped 91.44% in 2023, then surged 2097.51% in 2025.
- Over 5 years, Payables stood at $14.9 million in 2022, then plunged by 48.59% to $7.7 million in 2023, then plunged by 70.06% to $2.3 million in 2024, then soared by 2097.51% to $50.5 million in 2025, then rose by 15.45% to $58.3 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $58.3 million, $50.5 million, and $15.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | -7.73 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 2.72 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.80 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 497.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 1.73 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 808.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 427.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 986.00 Mn |
| 10 | Vireo Growth | 482.88 Mn | 340.58 Mn | 95.30 Mn | 125.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.30 Mn |
| Dec 31, 2025 | 50.50 Mn |
| Sep 30, 2025 | 15.07 Mn |
| Jun 30, 2025 | 47.45 Mn |
| Mar 31, 2025 | 6.46 Mn |
| Dec 31, 2024 | 2.30 Mn |
| Sep 30, 2024 | 3.76 Mn |
| Jun 30, 2024 | 9.18 Mn |
| Mar 31, 2024 | 2.11 Mn |
| Dec 31, 2023 | 7.67 Mn |
| Sep 30, 2023 | 1.48 Mn |
| Jun 30, 2023 | 27.09 Mn |
| Mar 31, 2023 | 15.60 Mn |
| Dec 31, 2022 | 14.93 Mn |
| Sep 30, 2022 | 17.24 Mn |
| Jun 30, 2022 | 2.53 Mn |
| Mar 31, 2022 | 17.69 Mn |
| Dec 31, 2021 | 14.81 Mn |
| Sep 30, 2021 | 9.53 Mn |
| Jun 30, 2021 | 1.30 Mn |